Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Ascelia Pharma AB ( (SE:ACE) ) is now available.
Ascelia Pharma AB has announced significant changes to its executive leadership team to enhance its operational capabilities and support future growth. Anton Hansson has been appointed as the new Chief Financial Officer, joining from KPMG, while Jennie Wilborgsson has been promoted to Chief Operating Officer. These changes aim to streamline the management structure and align with the company’s strategic priorities as it focuses on advancing its drug candidates, particularly Orviglance.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs that address unmet medical needs. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm under the ticker ACE. It currently has two drug candidates in development, Orviglance and Oncoral.
YTD Price Performance: 9.76%
Average Trading Volume: 1,492,063
Technical Sentiment Signal: Sell
Current Market Cap: SEK406.4M
See more insights into ACE stock on TipRanks’ Stock Analysis page.